Empirical Finance LLC cut its holdings in DaVita Inc. (NYSE:DVA – Get Rating) by 39.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 5,547 shares of the company’s stock after selling 3,598 shares during the period. Empirical Finance LLC’s holdings in DaVita were worth $631,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Nordea Investment Management AB increased its holdings in shares of DaVita by 96.6% during the 3rd quarter. Nordea Investment Management AB now owns 1,038,086 shares of the company’s stock worth $125,682,000 after buying an additional 510,106 shares during the last quarter. Renaissance Technologies LLC raised its stake in DaVita by 327.3% during the third quarter. Renaissance Technologies LLC now owns 389,300 shares of the company’s stock worth $45,260,000 after acquiring an additional 298,187 shares during the period. Allianz Asset Management GmbH increased its stake in shares of DaVita by 133.8% in the third quarter. Allianz Asset Management GmbH now owns 405,285 shares of the company’s stock valued at $47,118,000 after purchasing an additional 231,937 shares during the period. Teacher Retirement System of Texas increased its stake in shares of DaVita by 100.6% in the third quarter. Teacher Retirement System of Texas now owns 198,874 shares of the company’s stock valued at $23,121,000 after purchasing an additional 99,756 shares during the period. Finally, Morgan Stanley boosted its holdings in shares of DaVita by 17.2% in the third quarter. Morgan Stanley now owns 532,162 shares of the company’s stock valued at $61,869,000 after acquiring an additional 78,225 shares in the last quarter. Institutional investors own 84.28% of the company’s stock.
A number of equities analysts recently commented on the stock. Truist Financial raised their price objective on shares of DaVita from $114.00 to $125.00 and gave the stock a “hold” rating in a research note on Wednesday, January 5th. Zacks Investment Research upgraded shares of DaVita from a “sell” rating to a “hold” rating and set a $121.00 price target on the stock in a report on Tuesday, January 4th. Finally, StockNews.com upgraded shares of DaVita from a “buy” rating to a “strong-buy” rating in a report on Friday. Six research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $133.00.
NYSE:DVA opened at $121.45 on Monday. The firm has a market cap of $11.70 billion, a PE ratio of 13.68, a price-to-earnings-growth ratio of 1.47 and a beta of 1.18. DaVita Inc. has a 12 month low of $94.38 and a 12 month high of $136.48. The company has a quick ratio of 1.28, a current ratio of 1.32 and a debt-to-equity ratio of 9.32. The company’s 50-day moving average price is $114.06 and its two-hundred day moving average price is $110.56.
DaVita (NYSE:DVA – Get Rating) last posted its quarterly earnings results on Thursday, February 10th. The company reported $2.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.22. The business had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.91 billion. DaVita had a net margin of 8.42% and a return on equity of 77.78%. DaVita’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.67 earnings per share. On average, research analysts expect that DaVita Inc. will post 8.09 EPS for the current fiscal year.
About DaVita (Get Rating)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Get a free copy of the StockNews.com research report on DaVita (DVA)
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.